Overview: Calcitonin TestIntroduction: The Calcitonin Test measures calcitonin levels to diagnose thyroid cancer or bone disorders, causing neck lumps or bone pain. Following 2023 ATA guidelines, it uses an immunoassay for high sensitivity, aiding in endocrine screening. This test is critical for guiding diagnosis, treatment, and improving outcomes in endocrinology for patients with suspected thyroid or bone conditions.
Other Names: Calcitonin Assay, Thyroid Cancer Marker Test.
FDA Status: Laboratory-developed test (LDT), meeting endocrinology standards for diagnostic accuracy.
Historical Milestone: Calcitonin testing began in the 1960s with thyroid cancer research. Immunoassays emerged in the 1980s, and by the 2000s, high-sensitivity assays improved detection accuracy.
Purpose: Diagnoses thyroid cancer or bone disorders, guides treatment, and monitors calcitonin levels in patients with neck lumps or bone pain.
Test Parameters: 1. Calcitonin
Pretest Condition: Fasting for 10-12 hours required to stabilize calcitonin levels. Collect serum or plasma after overnight fasting. Report symptoms like neck lumps or bone pain, and list medications like bisphosphonates.
Specimen: 2-5 mL serum (SST) or 2-4 mL plasma (EDTA). Centrifuge within 1 hour. Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document neck lumps, bone pain, or family history of thyroid cancer or bone disorders. Include current medications, especially bisphosphonates or thyroid medications.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for thyroid or bone treatment.
Procedural Considerations: Uses an immunoassay to measure calcitonin levels. Results are available in 1-2 days, enabling rapid clinical decisions.
Factors Affecting Result Accuracy: Non-fasting samples or medications like proton pump inhibitors may alter results. Hemolysis or improper storage can degrade samples.
Clinical Significance: Elevated calcitonin levels indicate medullary thyroid cancer or bone disorders, prompting surgery or bisphosphonate therapy. Normal levels suggest alternative diagnoses.
Specialist Consultation: Consult an endocrinologist for result interpretation. An oncologist referral is advised for thyroid cancer cases.
Additional Supporting Tests: Thyroid ultrasound, fine-needle aspiration, or bone density scan to confirm thyroid cancer or bone disorders.
Test Limitations: False positives may occur with chronic kidney disease. Results require clinical correlation with imaging.
References: ATA Thyroid Cancer Guidelines, 2023; Thyroid, Haugen BR, 2022.
